Business Context and Reporting Period
Company: Acasti Pharma Inc. (Note: Input metadata referenced "Grace Therapeutics," but the filing text identifies the registrant as Acasti Pharma Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Thirteen-month period ended March 31, 2017 (Transition year; fiscal year-end changed from February 29 to March 31).
Business Overview: A clinical-stage biopharmaceutical company developing CaPre, an omega-3 (OM3) phospholipid derived from krill oil, for the treatment of severe hypertriglyceridemia (HTG). The company has no commercial revenue and relies on financing and strategic partnerships.
Key Financial Metrics
| Metric (CAD Thousands) | 13 Months Ended Mar 31, 2017 | Year Ended Feb 29, 2016 |
|---|---|---|
| Revenue from Sales | $0 | $0 |
| Net Loss | $(11,247) | $(6,317) |
| Loss Per Share (Basic & Diluted) | $(1.01) | $(0.59) |
| Non-IFRS Operating Loss | $(7,798) | $(6,569) |
| Cash and Cash Equivalents (End of Period) | $9,772 | $3,027 |
| Total Assets | $25,456 | $28,517 |
| Total Liabilities | $3,753 | $1,297 |
| Unsecured Convertible Debentures | $1,406 | $0 |
| Derivative Warrant Liabilities | $209 | $156 |
Note: All amounts in Canadian dollars (CAD) unless otherwise noted. The 2017 period includes 13 months of operations.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $4.9 million (78%) compared to the prior year. This was driven by a $1.2 million increase in Non-IFRS operating loss, a $2.2 million loss from changes in the fair value of warrant liabilities, and a $1.2 million increase in net financial expenses (primarily due to a shift from foreign exchange gains to losses).
- Financing Activities: The company raised significant capital in the 13-month period, including a public offering (gross proceeds ~$5.7 million) and a private placement of unsecured convertible debentures ($2.0 million principal). This resulted in a net increase in cash of $6.7 million.
- Liabilities: Total liabilities increased significantly due to the issuance of convertible debentures and an increase in trade payables related to research contracts and equipment purchases.
- Operating Expenses: Research and Development (R&D) expenses remained relatively flat on a total basis ($7.65 million vs $7.57 million), but General and Administrative (G&A) expenses increased by $1.5 million, largely due to increased salaries for full-time executive management and professional fees.
Guidance, Outlook, and Risks
- Going Concern Uncertainty: Management has disclosed a material uncertainty regarding the company's ability to continue as a going concern. Current assets are projected to be insufficient to support liabilities and expenses for the next 12 months, particularly given the costs associated with the planned Phase 3 clinical program for CaPre.
- Capital Needs: The company requires substantial additional funding to complete Phase 3 trials, obtain regulatory approval (NDA), and commercialize CaPre. Future financing is subject to market conditions and is not guaranteed.
- Development Timeline: The company plans to initiate its Phase 3 program in the second half of 2017. Commercialization is not anticipated until 2021 at the earliest.
- Regulatory Strategy: Acasti intends to pursue a 505(b)(2) regulatory pathway with the FDA, leveraging safety data from the approved drug LOVAZA. A "Bridging Study" was completed to support this approach.
- Key Risks:
- Failure to obtain regulatory approval for CaPre.
- Inability to raise additional capital on acceptable terms.
- Reliance on third-party manufacturers (CordenPharma) and suppliers (Neptune Technologies for krill oil).
- Intellectual property disputes and patent challenges.
- Competition from other OM3 products (e.g., LOVAZA, VASCEPA, EPANOVA).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.8 million cash balance against the projected burn rate for the upcoming Phase 3 trials and the timeline for the next financing round.
- Convertible Debentures: Review the terms of the $2.0 million unsecured convertible debentures issued in February 2017, specifically the conversion price ($1.90) and interest payment options (cash or shares).
- Phase 3 Initiation: Monitor the actual start date of the Phase 3 program (targeted for H2 2017) and patient enrollment rates.
- Related Party Transactions: Assess the dependency on Neptune Technologies (parent company) for shared services, raw materials (krill oil), and administrative support.
- Warrant Liability Volatility: Note the significant impact of stock price fluctuations on the fair value of derivative warrant liabilities, which can cause large non-cash swings in net loss.